Genmab — Juni 2016
-
well, jeg vil nu mene, at de ikke har den helt store tiltro. Programmet er jo sat igang dengang dara endnu ikke havde bevist sit værd. I dag er de håbløst bagefter
-
Det er om patentstriden mellem Morphosys og JNJ/Genmab. Intet nyt I forhold til tidligere
-
Hverken Morphosys eller JNJ vil kommentere sagen
-
Journalisten konkluderer selv, at de fleste sager ender i forlig pga uhyrlige sagsomkostninger
-
Genmab hits new highs as ASCO data bolster case for J&J-partnered cancer drug http://www.fiercebiotech.com/biotech/genmab-hits-new-highs-as-asco-data-bolster-case-for-j-j-partnered-cancer-drug
-
imorgen 16:50
-
-
Danske Capital med et fornuftig indspark om GEN - http://play.borsen.dk/share/57587481725ed7540a0d6ebf
-
Kursen flytter sig n
æppe. Pollux data er jo kendte. -
ved vi mere om pollux end det her? http://www.genmab.com/docs/default-source/default-document-library/24_dara-pollux-interim_positive_180516_uk.pdf?sfvrsn=2
-
jep, det gør vi (og så svarer jeg mig selv...) - http://learningcenter.ehaweb.org/eha/2016/21st/135347/antonio.palumbo.phase.3.randomised.controlled.study.of.daratumumab.bortezomib.html?f=p16m3l9759
-
93% ORR and 43% CR in POLLUX ph III
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind